Companion Pharmacogenetic Study to UMCC 9900/9901

University of Michigan Rogel Cancer Center

Status: Terminated

Conditions: Metastatic Breast Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT00146029

UMCC 3-27

Details and patient eligibility

About

The purpose is to examine the original breast tumor material to see how much of a metabolizing enzyme (CYP3A4) is present in tumor material. The researchers want to see if this is in any way associated with how the patient responded to docetaxel. They also want to examine the genes in the tumor that are responsible for the production of CYP metabolizing enzymes, to see if they are normal or if they have polymorphisms, or change compared to 'normal' CYP metabolizing enzymes.

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who participated on UMCC 9900/9901
• Living patients must give written informed consent

Exclusion criteria

• No tumor block tissue available